Navigation Links
Combination therapy reduced HER2-positive breast cancers
Date:12/10/2010

SAN ANTONIO A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

  • U.S. and Canada: (888) 282-7404
  • International: (706) 679-5207
  • Access Code: 25346432

Lead researcher Jos Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone.

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease," said Baselga, who is also a founding editor-in-chief of the AACR's newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

"It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting," said Baselga.

At the symposium, Baselga presented the primary outcome of tumor rate after surgery, as well as the secondary outcomes of objective response rate, safety, pathologic node-negative status, rate of conversion to breast conservation, disease free survival and overall survival.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
2. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
3. Grape news: New treatment combination safe alternative to sulfur dioxide
4. Study: Grass, fungus combination affects ecology
5. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
6. Diabetes drug kills cancer stem cells in combination treatment in mice
7. Old stain in a new combination
8. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
9. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
10. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology: